Updates on management of lipids beyond LDL-c and (new-onset) diabetes in preventive cardiology

Media formats available:

Preventive PCI versus only optimal medical therapy for vulnerable plaques
Preventive PCI versus only optimal medical therapy for vulnerable plaques
ACC.24
Preventive PCI versus only optimal medical therapy for vulnerable plaques
- Marc Bonaca, MD
Promising results for APOC3 ASO in familial chylomicronemia syndrome
Promising results for APOC3 ASO in familial chylomicronemia syndrome
ACC.24
Promising results for APOC3 ASO in familial chylomicronemia syndrome
- Erik Stroes, MD, PhD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
ACC.24
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
- Michael Koren, MD
Characteristics of patients with DM using icosapent ethyl in the real world
Characteristics of patients with DM using icosapent ethyl in the real world
Dyslipidemia
Characteristics of patients with DM using icosapent ethyl in the real world
- Om P. Ganda, MD

PACE-CME